Depression Clinical Trial
Official title:
A Phase 2A Study of Soy Isoflavones in the Treatment of Major Depression
The purpose of this study is to find out if the soy-based dietary supplement Novasoy
(Registered Trademark) is effective for the short-term treatment of clinical depression.
This study will also evaluate whether Novasoy (Registered Trademark) is effective in
treating the anxiety that often accompanies depression and will assess the best dose level.
Novasoy (Registered Trademark) is a marketed botanical dietary supplement containing soy
isoflavones. The active form of the soy isoflavone genistin may be a novel treatment for
neuropsychiatric illnesses. The soy isoflavone's specific hormonal properties may also have
beneficial effects on brain function in depressed patients.
This study will be conducted in two phases. During Phase I, participants will stop all
medications for at least 1 week. A psychiatric and medical examination will be conducted.
During Phase II, participants will be randomly assigned to receive either Novasoy
(Registered Trademark) or a placebo (an inactive pill) for 8 weeks. Participants who do not
respond to treatment after 5 weeks will be given a higher dose of their assigned medication.
After the 8-week period, participants will be monitored for up to 3 months before being
referred back to their clinician for further treatment.
Status | Completed |
Enrollment | 120 |
Est. completion date | April 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Subjects may be included in the study only if they meet all of the following criteria: Male or female subjects, 18 or older. Female subjects of childbearing potential must be using a medically accepted means of contraception as defined by one of the following: a) A barrier method of contraception. A barrier method of contraception is a physical barrier designed to prevent pregnancy, i.e., contraceptive foam or suppositories, spermicides, condoms, or diaphragm. b)Oral contraceptives, estrogen/progesterone-based or progesterone based. Women of childbearing potential also must have a negative serum beta-HCG at prestudy. Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol. Each subject must understand the nature of the study and must sign an informed consent document. Subjects must fulfill the criteria for major depression without psychotic features as defined in DSM-IV based on clinical assessment and confirmed by structured diagnostic interview SCID-P. Subjects must have a score at Visit 1 and Visit 2 of at least 20 on the MADRS (within 20%) and CGI-S greater than or equal to 3. EXCLUSION CRITERIA: Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry (Visit 1). Female subjects who are either pregnant or nursing. Patients initiating hormonal treatment (e.g., estrogen) in the last 3 months for mood, perimenopausal, or menstrual symptoms (OCP for birth control are acceptable but should not have been started in the last 2 month). Women ages 40-55 with irregular periods, or last menstrual period within the last 12 months, AND laboratory evidence confirming possible perimenopause, FSH greater than 14 IU/L. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. History of malignancies or neoplastic disorders. Any present or past history of breast carcinoma, or any woman with a family history of the following: premenopausal breast cancer or bilateral breast cancer in a first-degree relative; multiple family members (greater than 3 relatives) with postmenopausal breast cancer. History of porphyria. History of pulmonary embolus or thrombophlebitis. Women with a history of endometriosis, pelvic lesions, ovarian enlargement, or abnormal vaginal bleeding. Subjects with uncorrected hypothyroidism or hyperthyroidism. Subjects with one or more seizures without a clear and resolved etiology. Documented history of hypersensitivity to soy products. DSM-IV substance abuse (except nicotine and caffeine) within the past 90 days and substance dependence within the past 12 months. Treatment with a reversible monoamine oxidase inhibitor, guanethidine, or guanadrel within 2 week prior to Visit 2. Treatment with fluoxetine within 2 weeks prior to Visit 2. Treatment with any other concomitant medication with primarily CNS activity, other than specified in the Appendix. Current diagnosis of schizophrenia or other psychotic disorder as defined in the DSM-IV. Known allergy to soy or soy constituents. Judged suicidal risk based on use of the HAM-D suicide item greater than or equal to 3. Patients will not be allowed to receive a new course of structured psychotherapy during the trial. Patients will be excluded who have previously failed greater than 3 antidepressant trials by ATHF criteria. Patients will be excluded who have had ECT in the past 12 weeks. |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Mental Health (NIMH) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997 May 24;349(9064):1498-504. — View Citation
Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998 Jul;55(7):580-92. Review. — View Citation
Tohen M, Hennen J, Zarate CM Jr, Baldessarini RJ, Strakowski SM, Stoll AL, Faedda GL, Suppes T, Gebre-Medhin P, Cohen BM. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000 Feb;157(2):220-8. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |